PSMB4
ENSG00000159377
Target class
Enzyme
Chromosome
1
Approved drugs
3
Clinical candidates (approved and in development)
6
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- PSMB4
- Gene name
- Proteasome 20S subunit beta 4
- Gene symbol
- PSMB4
- Protein name
- Proteasome subunit beta type-4 (26 kDa prosomal protein) (HsBPROS26) (PROS-26) (Macropain beta chain) (Multicatalytic endopeptidase complex beta chain) (Proteasome beta chain) (Proteasome chain 3) (HsN3) (Proteasome subunit beta-7) (beta-7)
- HN3
- PROS26
- Gene biotype
- Protein coding
- Gene family
- Proteasome
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 509.32
- Tissue specificity (Gini)
- 0.191
- Tissue specificity (tau)
- 0.449
- KEGG gene identifiers
- hsa:5692
- Protein interaction confidence
- 0.940908
- Protein interaction partners
- 65
- R-HSA-1169091
- R-HSA-1234176
- R-HSA-1236974
- R-HSA-1236978
- R-HSA-174084
- R-HSA-174113
- R-HSA-174154
- R-HSA-174178
- R-HSA-174184
- R-HSA-180534
- R-HSA-180585
- R-HSA-187577
- R-HSA-195253
- R-HSA-202424
- R-HSA-211733
- R-HSA-2467813
- R-HSA-2871837
- R-HSA-349425
- R-HSA-350562
- R-HSA-382556
- R-HSA-450408
- R-HSA-4608870
- R-HSA-4641257
- R-HSA-4641258
- R-HSA-5358346
And 43 more, listed on the interactive page.
- End position
- 151401941
- Start position
- 151399556
- Chromosome
- 1
- Strand
- Forward
- Cytoplasm . Nucleus . Note=Translocated from the cytoplasm into the nucleus following interaction with AKIRIN2, which bridges the proteasome with the nuclear import receptor IPO9. .
- Mitochondria
- Nucleoplasm
- PubMed 12181345
- PubMed 34711951
- Tissue specificity (tau)
- 0.449215
- Expression inequality (Gini)
- 0.191461
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 509.32
- Cells - Cultured fibroblasts
- 468.87
- Uterus
- 432.76
- Artery - Aorta
- 427.21
- Cervix - Ectocervix
- 417.94
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes509.32
- Cells - Cultured fibroblasts468.87
- Uterus432.76
- Artery - Aorta427.21
- Cervix - Ectocervix417.94
- Cervix - Endocervix417.38
- Artery - Tibial410.52
- Fallopian Tube399.02
- Artery - Coronary384.62
- Nerve - Tibial370.32
- Ovary369.3
- Adipose - Subcutaneous361.89
- Colon - Sigmoid352.5
- Esophagus - Gastroesophageal Junction346.01
- Prostate338.5
- Pituitary336.46
- Esophagus - Muscularis335.6
- Bladder334.74
- Thyroid332.19
- Breast - Mammary Tissue330.93
- Skin - Sun Exposed (Lower leg)330.92
- Adrenal Gland330.87
- Spleen329.02
- Lung324.6
- Brain - Cerebellar Hemisphere319.94
And 29 more, listed on the interactive page.
- GO:0006979
- GO:0010498
- GO:0043161
- GO:0061136
- GO:0000502
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0005839
- GO:0036064
- GO:0070062
- GO:0005515
- GO:0140756
Related records
Trials (799)
- 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
- 3D PET Myocardial Blood Flow and Rb82 Infusion Profiles
- 4SCAR-T Therapy Post CD19-targeted Immunotherapy
- A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
- A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors
- A Clinical Study Evaluating the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Have Received Three or More Lines of Treatment
- A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
- A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
- A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors
- A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
- A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer
- A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
- A Hypoxia-Inducible CAR-T Cell Targeting AXL and CD73 for Advanced Gastric Cancer
- A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."
- A Multi-cohort Study of Safety, Efficacy, PK and PD of GNR-055 in Patients With Mucopolysaccharidosis Type II
- A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Drugs (6)
- Bortezomib D-mannitol 26S proteasome inhibitor
- Carfilzomib 26S proteasome inhibitor
- Ixazomib 26S proteasome inhibitor
- Ixazomib citrate 26S proteasome inhibitor
- Marizomib 20S proteasome inhibitor
- Oprozomib 26S proteasome inhibitor